How does Medivera Support Care
For all included studies, the intervention (retatrutide or LY3437943) was administered subcutaneously once weekly in multiple ascending doses, except in one single-dose pharmacokinetic study
Hence, we strongly encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with uncontrolled metabolic risks, i.e., especially those who need to lose weight and/or control high blood pressure
Individuals with a BMI of 30 or higher, or those with a BMI of 27 or higher with weight-related health conditions such as type 2 diabetes, hypertension, or high cholesterol, are suitable candidates for GLP injections
The above studies suggest that GLP-1 can downregulate the expression of SOCS-3 and SREBP-1c in rats with nonalcoholic fatty liver disease (NAFLD), reduce hepatic TG deposition